Tardive Dyskinesia Induced by Long‐Acting Injectable Paliperidone Palmitate Once Every 3 Months in a Patient With Schizophrenia: A Case Report and Literature Review Authors: Jianmiao Ge, Jing Li, Ruiting Ma, Lijun Tong, Qijing Bo, Zhiyang Zhang Published: 2026 ABSTRACT ABSTRACTProlonged use of long‐acting injectable antipsychotics may lead to tardive dyskinesia (TD). Clinicians should regularly assess the risk of TD. They should promptly discontinue the long‐acting medication, switch to an antipsychotic with a low risk of TD, and initiate supportive care as soon as signs of TD appear. Introduction Long‐acting injectable antipsychotics (LAIs) are an important option to prevent relapse in the maintenance treatment of schizophrenia. However, in practice, the management dilemma stemming from the irrevocability of long‐acting injections is often overlooked. Unlike oral antipsychotics, LAIs cannot be rapidly eliminated from the system once adverse events arise. TD is one of the most serious and challenging to manage adverse events associated with antipsychotic treatment. It is characterized by involuntary movements of the face, trunk, limbs, and other parts. The Article reports a case of TD induced by long‐acting Paliperidone palmitate once every 3 months (INVEGA TRINZA, PP3M) in a Patient with Schizophrenia, with the aim of enhancing the understanding of TD and offering clinical insights into its treatment, assessment, and prevention. Case History and Examination A 26‐year‐old female was admitted for the second time on March 12, 2025, with the primary complaints of “suspicion of being monitored for 4 years and facial tics for 5 months”. In 2021, she gradually became socially withdrawn, with a decline in academic performance, increased emotional sensitivity, and suspiciousness. She suspected others were speaking ill of her, believed she and her computer were being monitored, and insisted that her parents were not her biological parents but that she was the child of Elon Musk, founder of Tesla. She was first hospitalized in 2023 and diagnosed with schizophrenia. She was treated with paliperidone extended‐release tablets at 6 mg/day, and her symptoms improved one month later, which led to her discharge. Due to poor medication adherence, her outpatient treatment was gradually switched from long‐acting Paliperidone palmitate once a month (INVEGA SUSTENNA, PP1M) to PP3M. Her condition remained stable after the switch. Sixteen months after initiating PP3M, she developed frequent eye blinking, mouth opening, occasional tongue protrusion pressing against the palate, and involuntary twitching of the lips and mandible. Sixteen months after starting PP3M treatment, she developed frequent eye blinking, mouth opening, occasional tongue protrusion against the palate, and involuntary twitching of the lips and mandible. PP3M was immediately discontinued, and symptomatic treatment was initiated with deutetrabenazine tablets (24–42 mg/day), ginkgo biloba extract drops (6 mL/day), promethazine hydrochloride tablets (75 mg/day), and clonazepam tablets (1.5 mg/day). After 8 weeks of treatment, the therapeutic effect remained unsatisfactory, with persistent frequent eye blinking, mouth opening, tongue protrusion, and involuntary twitching of the lips and mandible. However, due to persistent involuntary movements, she was admitted for a second hospitalization. Physical examination: In the orofacial region, frequent involuntary eye blinking, twitching of the face and lips, and mouth opening with tongue protrusion were observed; in the extremities, muscle tone was slightly increased without choreiform movement. Psychiatric Examination: Conscious with intact orientation, passive contact, and relevant responses to questions. No sensory, perceptual, or perceptual disturbances were noted. No abnormalities in the form, logic, or content of thought. Attention span was adequate, gross intelligence assessment revealed no significant impairments, and memory was normal. The emotional state was stable, with coordinated and appropriate emotional responses. Basic instincts such as eating and sleeping patterns were normal; however, the patient exhibited decreased willpower. The insight section is presented. Auxiliary examinations included an admission Abnormal Involuntary Movement Scale (AIMS) score of 11 points. This comprised 4 points for facial expression muscles and jaw, indicating severe severity, and 3 points for the tongue, indicating moderate severity. The admission serum concentration of 9‐hydroxyrisperidone was 14.35 ng/mL, below the normal range of 20–60 ng/mL. Diagnosis and Treatment (Table 1) See Table 1. TABLE 1Changes in TD manifestations and AIMS scores during treatment.TimePatient's TD ManifestationsAIMS ScorePre‐treatmentNo TD manifestations016 months after PP3M treatmentEyes frequently blink, open mouth, occasionally appear on the top of the tongue jaw, lips, jaw involuntary jitter11Discontinuation of PP3M + Ginkgo biloba extract + deuterium butylphthalide + clonazepam + promethazine treatment for 1 monthThe involuntary blink of both eyes was improved compared with that before; the involuntary twitch of the lip and the jaw, and the action of opening the mouth and extending tongue were improved9The above treatment + switch to clozapine + metabolic therapy for 1 monthThe blink of both eyes, the twitch of lips and jaws were improved, but the mouth and tongue could not be controlled6Oral drug treatment 1 month after dischargeEye blinking, lip and lower jaw twitching, eye blink, lips, jaw twitching decreased significantly, mouth opening frequency decreased, tongue, and mouth together5Oral medication 2 months after discharge from the hospitalAlmost no involuntary eye blinking, almost no more involuntary blinking, mouth, tongue, and no significant abnormal involuntary movement3 Changes in TD manifestations and AIMS scores during treatment. Conclusion This case clearly illustrates the unique challenges of managing TD risk in patients receiving long‐acting injectable antipsychotic therapy. A critical issue with long‐acting formulations is that once administered, the drug cannot be removed. Therefore, extreme caution is warranted in patients with a history of TD, those of advanced age, individuals with long‐term exposure to first‐generation antipsychotics (FGAs), or those with comorbid mood disorders. In such cases, alternative treatment strategies should be prioritized. Enhanced informed consent must be obtained prior to treatment initiation. Patients and their families need to understand that managing TD in the context of long‐acting formulations is particularly challenging and time‐consuming, which is an essential consideration in shared treatment decision‐making. Furthermore, a mandatory AIMS assessment, documented by video recording, should be performed before each injection to establish a baseline and monitor subtle changes over time. If early signs of TD emerge, subsequent injections should be suspended immediately. A multidisciplinary team—including psychiatrists, neurologists, and movement disorder specialists—should collaborate to develop a comprehensive long‐term management plan that addresses symptom control, functional rehabilitation, and psychological support. Discussion TD is a movement disorder characterized by irregular, involuntary movements. It most commonly affects the tongue, lips, jaw, and facial muscles, and may occasionally involve the periorbital region. In some cases, abnormal movements of the trunk and extremities may also occur [1]. TD typically develops in patients on long‐term antipsychotic or dopamine receptor blocker therapy, leading to a marked decline in quality of life [2]. The pathophysiological mechanism underlying TD remains incompletely understood, although several neurotransmitter pathways have been proposed, including the dopamine supersensitivity hypothesis, the gamma‐aminobutyric acid (GABA) hypothesis, and the oxidative stress and neurotoxicity hypothesis [3, 4, 5, 6]. Among these, the dopamine supersensitivity hypothesis is the most widely accepted; it posits that overexpression of dopamine D2 receptors leads to increased receptor sensitivity and subsequent movement disorders [7, 8]. TD is a persistent and potentially irreversible movement disorder associated with dopamine receptor antagonist therapy [9]. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) [10], TD is defined as a drug‐induced movement disorder resulting from exposure to antipsychotics or other dopamine‐blocking agents for at least three months (or one month in individuals aged 60 years or older). In clinical practice, particularly in Europe and other regions, the Schooler‐Kane criteria (SK criteria) are sometimes employed as a diagnostic aid for TD [11]. The diagnostic criteria for TD [12] are as follows: (1) a total duration of antipsychotic treatment of ≥ 3 months; (2) the presence of mild dyskinetic movements (AIMS score ≥ 2) in ≥ 2 body regions (e.g., face, lips, tongue, upper limbs, lower limbs, trunk), or moderate dyskinetic movements (AIMS score ≥ 3) in one body region (Schooler‐Kane criteria [12]); alternatively, a minimum total AIMS score of 3 with at least one body region scoring ≥ 2 (Glazer & Morgenstern criteria [13]); (3) exclusion of other diseases that may cause involuntary movements. International studies indicate that females are at a higher risk of developing TD than males [14, 15]. An early review of 39,187 individuals reported a significantly higher TD prevalence in females (26.6%) compared with males (21.6%) [16]. Moreover, Asians appear to have a lower risk of TD relative to other ethnic groups, possibly due to underlying protective ethnic factors [17]. Studies conducted in the Chinese population have identified male sex, advanced age, and low educational level as risk factors for TD [18]. TD symptoms are closely correlated with age. As age advances, metabolic function declines, which impairs drug absorption and processing and may consequently reduce the efficacy of pharmacotherapy [19, 20]. Patients with a low educational level often exhibit cognitive impairment and poor medication adherence, both of which contribute to suboptimal treatment outcomes [21, 22]. The present early in the course of antipsychotic treatment. Collectively, these findings suggest that TD is significantly associated with sex and the presence of early extrapyramidal symptoms. Furthermore, studies have suggested that a high frequency of hospitalizations and a prolonged disease course are associated with an increased risk of TD [18]. The patient in this case had a continuous disease course of four years. She developed persistent orofacial movement disorders 8 weeks after 16 months of PP3M treatment, which manifested as eye blinking, involuntary twitching of the cheeks and lips, and mouth opening. Upon admission, her AIMS score was 11 points. Over time, her TD symptoms gradually worsened with disease progression. In addition, comorbid conditions such as diabetes and hypertension have been identified as risk factors for TD. Notably, diabetic patients tend to have a higher incidence and greater severity of TD than non‐diabetic patients [16]. This may be attributed to diabetes‐induced neurological and vascular lesions, which impair the function of motor control centers and associated pathways [23, 24]. Consequently, motor control is compromised in TD patients, and treatment response may be diminished. Similarly, hypertension can lead to cerebral vascular lesions, further impairing motor function and exacerbating TD symptoms [25]. Clinical studies have demonstrated that second‐generation antipsychotics (SGAs) produce less dopamine D2 receptor blockade than FGAs [26]. A 2017 PubMed literature review reported a TD prevalence of 20.7% among patients treated with SGAs, which was significantly lower than the 30.0% observed in those treated with FGAs. Geographically, the prevalence of TD was 17.3% in Asia, 22.3% in Europe, 31.3% in the United States, and 31.8% in other regions, including Africa, Australia, and the Middle East. A meta‐analysis further indicated that, after controlling for age and geographic region, antipsychotic type remained a significant factor [17]. Although SGAs are associated with a lower risk of TD compared with FGAs, clinical vigilance should not be relaxed. The rapid onset of TD in this patient, despite SGA treatment, serves as a cautionary reminder. LAIs achieve steadier and more effective plasma concentrations than oral formulations. By eliminating the need for daily dosing, they address a major barrier to optimal medication adherence in many patients. LAIs have been shown to significantly reduce both relapse and rehospitalization rates (evidence level: 1a) [27]. Currently, several clinical guidelines [20, 28, 29] recommend LAIs as a key strategy for the continuous treatment of schizophrenia [30]. In full‐course management of schizophrenia, risperidone LAIs are pharmacokinetically equivalent to their oral counterparts but produce smaller plasma concentration fluctuations, ensuring continuous and stable drug release. The incidence of injection site pain with these agents is low, and other adverse effects are comparable to those observed with oral formulations. Consequently, the patient was treated with LAI‐SGA paliperidone, which not only ensured regular follow‐up but also reduced the risk of intentional or unintentional overdose [31, 32]. PP3M is currently the only long‐acting antipsychotic administered on a three‐month injection schedule [33]. In patients with schizophrenia treated with PP3M, relapse rates have been reported as 5% at three years [33] and 7% at two years [34]. Given these efficacy data, the patient opted for PP3M to improve medication adherence. We summarized four previously reported cases of TD induced by paliperidone LAIs [35, 36, 37, 38]. These included three females and one male, with a mean age of 41.25 years. TD manifestations involved facial and oral movements in three cases and trunk movements in one case. The mean AIMS score was 9.5 points. Outcomes varied following intervention: In one case, TD symptoms improved after drug discontinuation alone [35]; in another, the patient was switched to aripiprazole combined with vitamin E after discontinuation, resulting in complete resolution of TD and an AIMS score of 0 after one month [37]; in a third case, no improvement was observed after discontinuation and switching to clonazepam, amantadine, baclofen, and olanzapine, but TD symptoms eventually improved six weeks after transitioning to clozapine [38]; in the remaining case, the patient was switched to olanzapine combined with clonazepam after discontinuation of paliperidone. However, involuntary movements persisted at three months of follow‐up [36] (Table 2). TABLE 2Analysis of clinical characteristics of TD cases induced by paliperidone long‐acting injectable (n = 4).Author & Publication YearPatient AgeGenderTD ManifestationsAIMS ScoreTreatment RegimenOutcomeVacLav Hyrman 198533FemaleStiff movements, mask face, Parkinson's hand tremors, obvious chewing movements, limb movement instability—Discontinuation of injectionImprovedJohn Lally 201349FemaleTongue, lips, tongue, chin involuntary movement, repeated bite, mandibular lateral chewing movement, pouting6Withdrawal, switch to olanzapine 10 mg/day, clonazepam 2 mg/day.After 6 weeks of withdrawal, there was some improvement; after 3 months of drug withdrawal, except for continuous involuntary movement, the symptoms were basically alleviatedAlber 201255MaleThere was an involuntary transverse oscillation motion in the middle of the neck, and an obvious involuntary and continuous rhythmic motion in the hyoid region of the neck.13Withdrawal, switch to aripiprazole 30 mg/day, vitamin E 800 IU twice a day.The symptoms of TD were improved after 6 weeksChia‐Hao Ma 201628FemaleDifficult swallowing liquid, suffocation, limited mouth opening, tight jaw, clumsy tongue—After switching to clonazepam, amantadine, and baclofen, it was ineffective; olanzapine was ineffective after discontinuation, and clozapine was used at 75 mg/day.TD symptoms improved at 6 weeks Analysis of clinical characteristics of TD cases induced by paliperidone long‐acting injectable (n = 4). In the present case, TD developed 16 months after initiation of PP3M. The symptoms predominantly involved facial and oral movements, including the muscles of facial expression, lips, periorbital region, jaw, and tongue. This clinical presentation is consistent with the four previously summarized cases of TD induced by paliperidone LAIs. Some studies have suggested that the incidence of TD with long‐acting injectable formulations appears higher than with oral medications, although the difference did not reach statistical significance [39]. Other studies have found that the incidence of TD is significantly lower in patients treated with LAI‐SGAs, with the lowest rates observed among those receiving paliperidone LAIs [37]. The mechanism by which PP3M induces TD remains incompletely understood. Potential risk factors include high antipsychotic doses, intermittent antipsychotic treatment, and concurrent use of anticholinergic drugs [40]. In the present case, the patient developed prolonged orofacial movement disorders, which may be significantly associated with the extended duration of LAI use [16]. Moreover, the prolonged elimination half‐life of PP3M implies that once adverse reactions such as TD occur, achieving adequate control will require a longer time frame. TD is often difficult to reverse once established, with a spontaneous remission rate of only 2.0% after complete drug withdrawal [41, 42, 43]. Therefore, active, routine, and systematic screening for TD symptoms should be implemented in all patients receiving antipsychotic therapy. Studies have identified several pharmacological options for TD, including deutetrabenazine, valbenazine, tetrabenazine, benzodiazepines, amantadine, vitamin E, vitamin B6, and GABA agonists [9]. Currently, the novel vesicular monoamine transporter 2 (VMAT2) inhibitors, such as deutetrabenazine and valbenazine, are recommended as first‐line agents for TD treatment worldwide [24]. These agents reduce presynaptic dopamine release by inhibiting VMAT2, thereby alleviating TD symptoms resulting from long‐term use of dopamine receptor antagonists [25]. In the present case, PP3M was immediately discontinued following the onset of TD. Symptomatic treatment was subsequently initiated with deutetrabenazine tablets (24 mg/day), combined with ginkgo biloba extract drops, promethazine hydrochloride tablets, and clonazepam tablets. No significant improvement was observed after the initial 4 weeks of treatment; the dosage of deutetrabenazine was therefore increased to 42 mg/day, but the therapeutic effect remained unsatisfactory after another 4 weeks. Following 8 weeks of combination therapy with the four agents, the patient showed no meaningful improvement in TD symptoms, posing a considerable clinical challenge. Relevant literature has reported that continuous deutetrabenazine treatment for up to 145 weeks can yield sustained improvements in AIMS scores [44]. After admission, the patient received intravenous infusion to promote drug metabolism, and the deutetrabenazine dose was further titrated to a maximum of 48 mg/day; however, the clinical response remained limited. It is therefore recommended to consider switching to clozapine as an alternative treatment option. Clozapine [24] exerts multiple receptor‐blocking effects and binds only transiently to dopamine D2 receptors, with rapid dissociation, which contributes to its low risk of extrapyramidal symptoms [45]. This pharmacological profile may help reduce the severity of TD symptoms. Based on this rationale, the treatment regimen was adjusted to include clozapine in combination therapy. After 16 weeks of treatment, the AIMS score continued to improve. Studies have demonstrated that TD symptoms are associated with continuous exposure to dopamine receptor blockers, such as antipsychotics [25]. Switching from FGAs to SGAs with low D2 receptor affinity, such as clozapine or quetiapine, can effectively alleviate symptoms [29]. Pardis P [46] analyzed 13 studies involving 905 patients and reported that clozapine reduces TD severity over time, with AIMS score reductions ranging from 7.7% to 99.8%; notable improvements were observed as early as 4 to 5 weeks. Many pharmacological agents for TD remain experimental, rendering its management a significant clinical challenge. Once TD occurs, it is recommended to select antipsychotics with a lower risk of TD and to carefully assess individual risk factors [10]. Accordingly, clinicians should perform AIMS assessments before and during treatment to facilitate early detection of abnormal involuntary movements and enable timely intervention. The APA guidelines recommend monitoring patients on FGAs every six months and those on SGAs every 12 months [47]. Patients receiving long‐term antipsychotic therapy should undergo regular screening, with enhanced use of standardized rating scales and close monitoring of other known adverse drug reactions. Furthermore, a multidisciplinary approach is essential for patients presenting with more severe or complex symptoms [10]. Limitations: While video recordings are invaluable for demonstrating the clinical manifestations of TD, they were not obtained during the patient's hospitalization. This decision was made out of strict adherence to patient privacy and ethical guidelines, as specific informed consent for video documentation had not been secured prior to the evaluation. Given that the patient has been discharged with significant clinical improvement, retrospective video acquisition is no longer feasible. Consequently, we have endeavored to provide a comprehensive and detailed written description of the TD presentation in the text. Author Contributions Jianmiao Ge: methodology, writing – original draft. Jing Li: conceptualization, resources. Ruiting Ma: data curation, software. Lijun Tong: formal analysis, supervision. Qijing Bo: project administration, writing – review and editing. Zhiyang Zhang: funding acquisition, validation. Funding Beijing Municipal Administration of Hospitals Incubating Program (PZ2025029) and Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences (2025GLLH0286). Ethics Statement All procedures performed in this study were in accordance with the ethical standards of the Helsinki Declaration (as revised in 2013). Consent Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article. Conflicts of Interest The authors declare no conflicts of interest.